Loading... Please wait...
Categories
New Products
-
$350.00 -
$95.00 -
$175.00 -
$550.00 -
$790.00
Our Newsletter
Product Description
Decitabine is a cytosine nucleoside analog that acts as a potent inhibitor of DNA methylation. Decitabine can be incorporated into DNA and inhibits further DNA methylation and induce apoptosis and senescence in leukemic cells. [1]
In a panel of primary (acute myeloid leukemia) AML cultures, Decitabine significantly inhibited proliferation and reduced cell viability with IC50 10-60 nM. [2]
Decitabine shows activity in a broad range of hematologic disorders. Currently, Decitabine is being studied in a Phase III clinical trials in patients with myelodysplastic syndrome (MDS) [3] and in a Phase II clinical trials in patients with AML [4].
Technical information:
| Chemical Formula: | C8H12N4O4 | |
| CAS #: | 2353-33-5 | |
| Molecular Weight: | 228.21 | |
| Purity: | > 98% | |
| Appearance: | White | |
| Chemical Name: | 4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one | |
| Solubility: | Up to 100 mM in DMSO | |
| Synonyms: | Decitabine, Deoxycytidine, 5-Aza-2?-deoxycytidine |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder or DMSO solution at -20oC desiccated.
Reference:
| 1. | Decitabine is a cytosine nucleoside analog that acts as a potent inhibitor of DNA methylation. Decitabine can be incorporated into DNA and inhibits further DNA methylation and induce apoptosis and senescence in leukemic cells. [1] In a panel of primary (acute myeloid leukemia) AML cultures, Decitabine significantly inhibited proliferation and reduced cell viability with IC50 10-60 nM. [2] Decitabine shows activity in a broad range of hematologic disorders.Decitabine has been approved for treatment of myelodysplastic syndrome (MDS) [3] and is in a Phase II clinical trial in patients with acute myelogenous leukemia (AML). [4] Pubmed ID: 21044612 |
| 2. | Leonard SM, et al. Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia. PLoS One. 2014; 9(1):e87475 Pubmed ID: 24489920 |
| 3. | Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia. clinicaltrials.gov/NCT00049582 |
| 4. | An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy. clinicaltrials.gov/NCT02472145 |
Other Information:
Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.
